ERBB2 and breast carcinoma: For patients with HER2-positive breast cancer, several new targeted drugs have been specifically used for the treatment in the past 10 years, including the application of trastuzumab and pertuzumab, which have significantly improved the survival rate of patients, indicating that targeted therapy is a powerful means for the treatment of breast cancer (8).